EU Clarifies ‘Administrative Process’ Of Switching Trials To CTR

The European Commission’s updated guidance on transitioning studies from the Clinical Trials Directive to the Clinical Trials Regulation reflects the agreement reached by the member state representatives in the Clinical Trials Advisory Group.

Check list and marker
The European Commission Says Transitioning Applications Should Not Be Reassessed • Source: Shutterstock

The European Commission has issued updated guidance that addresses concerns sponsors have had over the need to switch ongoing clinical trials authorized under the erstwhile EU Clinical Trials Directive (CTD) to the Clinical Trials Regulation (CTR). 

Ongoing trials that are not expected to end by 30 January 2025 must be transitioned to the CTR by submitting a “transitioning application” to the Clinical Trials Information System (CTIS)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

EMA: ‘Sad To See’ Member States Against Patient Engagement Under EU Pharma Reform

 

The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By 

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

Why Hympavzi Secured English Funding For Hemophilia B But Not Hemophilia A

Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.

EMA Rejects Treatments For Pediatric Myopia & CTCL

 
• By 

EU marketing applications for drugs aimed at slowing myopia progression in children and for treating cutaneous T-cell lymphoma have been turned down by the European Medicines Agency.

More from Geography

US Most Favored Nations Policy: Higher Drug Spending In Germany Is ‘Difficult To Imagine’

 

Germany’s federal health care decision-making body, the G-BA, tells the Pink Sheet that German drug prices are fair and speculation of price rises in the market due to the US MFN policy is fear mongering.

Autolus’s Aucatzyl And GSK’s Blenrep Among 10 New Drugs To Get EMA Nod

 
• By 

The European Medicines Agency has OKd 10 new medicines for EU-wide approval, including a CAR-T therapy for treating acute lymphoblastic leukemia. Two drugs were, however, rejected.

Europe’s UPC Issues Landmark Ruling On Second Medical Use Claims

 

The verdict by the Unified Patent Court in the dispute between Sanofi/Regeneron Pharmaceuticals and Amgen explains what companies should look out for when deciding whether infringement has taken place when it comes to second medical use patents.